|
|
 |
|
Viewing report
|
|
|
|
European Autoimmune Diseases Therapeutics Markets
Frost & Sullivan, Jan 2007
This Frost & Sullivan research service titled European Autoimmune Disease Therapeutics Market provides an overview of current treatment options, drugs in pipeline and technological advancements in the market. It also a complete analysis of key market drivers, restraints and revenues involved in the current rheumatoid arthritis and multiple sclerosis medications. In this research, Frost & Sullivan's expert analysts thoroughly examine the following therapeutics markets for rheumatoid arthritis and multiple sclerosis.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
-Rheumatoid arthritis therapeutics
-Multiple sclerosis therapeutics
Market Overview
Autoimmune Disease Therapeutics Market to Gain from Increased Acceptance of Biologics by Physicians
The European autoimmune diseases therapeutics market is set to witness sustained growth in the coming years. Autoimmune diseases are caused by body’s immune responses directed on its own tissues. The immune system is designed to attack the infections caused by foreign bacteria and viruses. However, in an autoimmune disease, the immune cells in the body recognise the body’s own tissues as ‘foreign’ and the antibodies released by the immune cells act on various tissues in the body, leading to various disease conditions. There are over 70 autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis (MS) and psoriasis. It has been estimated that the prevalence rate of multiple sclerosis in Europe is 83 out of 100,000. Moreover, it is more common among women than men. In addition to this, two million people in Europe are affected by RA, which is one of the most common forms of autoimmune diseases, affecting 21 million people worldwide. However, the societal burden of autoimmune diseases is difficult to estimate as most of these diseases are debilitating, while some are less serious.
'The growing patient population and the need for better treatment options are the major driving forces in the autoimmune diseases therapeutics market in Europe,' notes the analyst of this research service. 'The increased uptake of biologics by physicians is also likely to have a significant impact on the sales of autoimmune disease therapeutics.' In addition, aggressive educational campaigns undertaken by pharmaceutical companies to promote new biologics are igniting interest among physicians and are expected to contribute to an increase in market revenues.
Awareness Programmes Crucial for Market Growth
Currently, the huge gap that exists between early diagnosis and the initiation of therapy is a critical factor restraining market growth. 'The complex nature of autoimmune diseases hinders the development of drugs that can cure these diseases,' explains the analyst. 'This scenario is worsened by low awareness of autoimmune diseases among patients, as well as physicians.' Thus, immense scope exists for improvement in translating the current knowledge of the autoimmune diseases to produce efficient therapeutics that can address the symptoms, as well as cure the disease.' Accordingly, researchers are striving to develop better therapeutics to reduce the burden of autoimmune diseases.
Meanwhile, various continuous medical education programmes will need to be conducted to inform the community about the implications of autoimmune diseases. These initiatives will promote the treatment of those affected with rheumatoid arthritis or multiple sclerosis and some form of drug for such autoimmune diseases can be administered to them.
|
|
|
|
